Inside the Test: What an Endometrial Biopsy Can—and Cannot—Tell You

Procedure guide

“We need to do an endometrial biopsy” can sound like “we think you have cancer.” That is not what the recommendation means. Biopsy is used for many bleeding and ultrasound findings because tissue—not symptoms alone—can show what the uterine lining is doing.

The test is often performed quickly in an office. The pain, however, varies enormously. You deserve an explanation of why it is being proposed, what will happen, what pain-control options are available, what happens if office sampling does not work, and what the pathology can actually answer.

IN THIS ARTICLE +

1. Why is an endometrial biopsy recommended?
2. What tissue is being sampled?
3. What happens during an office biopsy?
4. If the biopsy is offered unexpectedly
5. How much does an endometrial biopsy hurt?
6. Pain control: what the evidence supports—and where it is mixed
7. How to ask for a real pain-management plan
8. Consent continues while the procedure is happening
9. What if the instrument cannot pass or the sample is inadequate?
10. Biopsy, hysteroscopy and D&C are not the same test
11. The transvaginal ultrasound and your endometrium
12. After an uncomplicated office biopsy
13. What happens while you wait for results?
14. What the pathologist is actually looking at
15. A benign biopsy—but the bleeding returns
16. Questions to ask before the appointment
17. Sources

Why is an endometrial biopsy recommended?

The aim is usually to explain abnormal bleeding or an endometrial finding—not to confirm a conclusion already made. Sampling may be considered for:

• bleeding after menopause;
• abnormal uterine bleeding in perimenopause when age, pattern, persistence or risk factors make tissue assessment appropriate;
• persistent or recurrent bleeding;
• endometrial thickening, heterogeneity, increased vascularity, a possible focal lesion or another relevant ultrasound finding;
• follow-up of endometrial hyperplasia or treatment response;
• bleeding in an MHT/HRT context that needs investigation; or
• other clinical situations in which examining endometrial tissue may change care.

“But isn’t irregular bleeding normal in perimenopause?”

Irregular bleeding is common during perimenopause because ovulation and hormone patterns become less predictable. Common does not mean every pattern should automatically be attributed to the transition. Very heavy or prolonged bleeding, bleeding between periods or after sex, persistent changes, anemia, and bleeding in a higher-risk clinical context may warrant investigation. Age, the exact pattern, medications, pregnancy possibility, ultrasound findings and risk factors all affect the threshold for sampling.

Postmenopause and MHT are different contexts

After menopause, new vaginal bleeding needs assessment. Most postmenopausal bleeding is not caused by endometrial cancer, but bleeding is the symptom through which many endometrial cancers are found, so it should not be dismissed.

With menopausal hormone therapy, interpretation depends on whether the regimen is continuous or cyclic, when treatment started or changed, which estrogen and progestogen are used, adherence, how long bleeding has continued and other clinical findings. Some bleeding can occur early in treatment or on a planned cyclic regimen; MHT does not make all bleeding benign. See Maple’s Canadian MHT/HRT guide and menopause-symptoms guide.

What tissue is being sampled?

The pathway is simple to picture: vagina → cervix → uterine cavity → endometrium. The cervix is the narrow opening into the uterus. The endometrium is the tissue lining the inside of the uterine cavity. That lining is what the biopsy collects.

A common Pipelle biopsy uses a thin suction instrument. It is usually performed in a gynecology office, outpatient clinic, hospital-based gynecology setting or an appropriately equipped primary-care setting. It is not normally operating-room surgery—but an office procedure is not the only possible pathway when sampling is unsuccessful or cannot reasonably be tolerated.

What happens during an office biopsy?

1. You undress from the waist down and lie on an examination table, usually with your feet supported.
2. A speculum is placed in the vagina so the clinician can see the cervix. This can produce pressure or stretching.
3. The cervix may be cleaned or prepared.
4. If stability or alignment is needed, a tenaculum or another instrument may hold the cervix. This can feel like a pinch, sharp pain or cramp.
5. The clinician identifies the cervical opening. Sometimes a narrow sound or dilator is used to assess the path or help entry.
6. A thin sampling instrument passes through the cervix into the uterine cavity. Passage through the cervical opening may cause sharp discomfort or cramping.
7. Suction is created and the instrument is moved to collect small endometrial fragments. Uterine instrumentation and contractions can create strong, wave-like cramps.
8. One or more passes may be made when needed to obtain tissue.
9. The instruments are removed. Cramping may settle quickly or continue for a while.
10. The tissue is placed in a labelled specimen container and sent to pathology.

The sampling portion may last seconds, while check-in, consent, positioning, examination, preparation and recovery make the appointment much longer.

If the biopsy is offered unexpectedly

A clinician may offer sampling during an appointment because the equipment, time and expertise are available. Being technically ready to perform it is not the same as having completed informed consent.

You should understand why it is recommended, what will happen, likely discomfort or pain, important risks and limitations, available pain-management approaches and reasonable alternatives where applicable. If the situation is not emergent and you feel unprepared, a useful question is:

“Does this need to be done today, or can we schedule it after we discuss pain control and preparation?”

That question does not assume postponement is safe. It asks the clinician to explain the medical timing.

How much does an endometrial biopsy hurt?

There is no honest universal answer. Cervical manipulation, passage through the cervix, contact with the uterine cavity and uterine contractions can all contribute. Anatomy, cervical narrowing, procedural difficulty, previous painful procedures, chronic pelvic pain, trauma history, anxiety and individual nervous-system responses may affect the experience. Evidence does not justify promising that childbirth history will reliably predict pain.

Some people feel pressure, a pinch and brief moderate cramps. Some feel several seconds of significant pain. Others have pain severe enough that the procedure must stop. Good counselling makes room for all three possibilities without predicting catastrophe.

Pain control: what the evidence supports—and where it is mixed

Technique also matters: clear communication, allowing time for anaesthetic effect, minimizing unnecessary cervical traction or passes, and stopping when requested can affect the experience. No intervention guarantees a painless procedure.

How to ask for a real pain-management plan

• “What pain-control options do you offer for an endometrial biopsy?”
• “What can we do beforehand and during the procedure to reduce pain?”
• “Do you offer local anaesthetic or a cervical/paracervical block when appropriate?”
• “I’ve had a very painful cervical or uterine procedure before. Can we make a plan before we start?”
• “If I cannot tolerate an office biopsy, what happens next?”
• “Should I take anything beforehand, and is it safe with my medications and medical history?”

These are ordinary preparation questions for a medical procedure, not adversarial demands.

Consent continues while the procedure is happening

You can say that the procedure is too painful and ask the clinician to pause or stop. That may mean an adequate sample cannot be obtained, so the original medical question remains unresolved and another plan may be needed. Ongoing consent is not a promise that stopping has no consequences; it means you remain part of the decision while those consequences are explained.

What if the instrument cannot pass or the sample is inadequate?

Office sampling can be difficult because the cervix is narrow or scarred, the uterine angle is challenging, pain limits the attempt, the device does not reach the cavity, or very little tissue is present. After menopause, cervical stenosis and a thin, inactive endometrium can contribute.

Depending on the reason for biopsy, bleeding pattern, ultrasound and the attempt itself, the next step may be no immediate repeat, a repeat with a different preparation or pain plan, specialist assessment, hysteroscopy, or dilation and curettage (D&C) in an appropriate setting. Cervical-preparation medication is not routine for everyone and can itself cause cramping and other effects.

Biopsy, hysteroscopy and D&C are not the same test

• Office endometrial biopsy: collects a small blind tissue sample. It samples the lining but does not visually inspect every part of the cavity.
• Hysteroscopy: passes a small camera through the cervix, allowing direct inspection and potentially targeted biopsy or treatment of a focal lesion such as a polyp.
• D&C: dilates the cervix and removes or samples endometrial tissue. It may be used with hysteroscopy or in selected procedural settings; it is not automatically the “better biopsy.”

Hysteroscopy or another approach may be considered after unsuccessful or insufficient office sampling, when imaging suggests a focal abnormality, or when bleeding persists or recurs despite reassuring blind sampling.

The transvaginal ultrasound and your endometrium

A transvaginal ultrasound (TVUS) is often part of the investigation of abnormal bleeding in perimenopause or bleeding after menopause. It answers a different question from an endometrial biopsy: ultrasound examines structure and appearance; biopsy examines actual tissue under a microscope.

What actually happens during a transvaginal ultrasound?

TVUS is usually performed in a hospital imaging department, community diagnostic-imaging clinic or gynecology service. You undress from the waist down and lie on an examination table. A trained sonographer or physician places a protective cover and lubricating gel over a slim ultrasound transducer, then gently inserts it into the vagina. The transducer stays in the vagina. It does not pass through the cervix or enter the uterus.

The operator angles and rotates the transducer to obtain images from several directions. Because it sits close to the pelvic organs, it can provide detailed views of the uterus, the endometrial lining and, when visible, the ovaries and surrounding adnexal areas. The scan may also show fibroids, suggest a polyp or another focal abnormality, identify fluid or changes in uterine anatomy, and reveal some ovarian or other pelvic findings. Ultrasound does not reliably identify every lesion, and a report may say that an ovary or part of the endometrium was not fully seen.

The examination commonly feels like pressure, fullness or discomfort as the transducer is moved. Tenderness can be greater with pelvic pain, vaginal dryness, muscle guarding or certain pelvic conditions. Tell the sonographer if something hurts; you can ask them to pause or stop. Appointment logistics vary, but the scan itself is often completed in roughly 15 to 30 minutes, with the internal portion sometimes shorter. A transabdominal scan may be done as well, sometimes requiring a full bladder before you empty it for the transvaginal portion.

Physically, this is very different from an endometrial biopsy. TVUS places an imaging probe in the vagina but not through the cervix. A biopsy uses a speculum and passes a thin sampling instrument through the cervical opening into the uterine cavity to collect tissue. Ultrasound creates images; it does not remove tissue.

What does “endometrial thickness” mean?

The endometrium is the lining of the uterine cavity. On a good midline ultrasound view, the clinician measures the combined front-and-back layers of that lining at their thickest point—often called the double-layer endometrial thickness or endometrial echo. Fluid inside the cavity is generally excluded from the tissue measurement. The number is reported in millimetres.

That measurement describes an image. It does not reveal what individual cells are doing, and its meaning depends heavily on why the scan was ordered, whether bleeding is occurring, menopausal stage, MHT/HRT regimen, the appearance of the lining and how completely it could be seen.

Postmenopausal bleeding: what is the approximately 4-mm threshold for?

For someone with postmenopausal bleeding who is not being assessed under a different MHT-specific pathway, many guidelines use a clearly visualized endometrium of about 4 mm or less to help identify a low-risk group. ACOG reports that this finding has a greater than 99% negative predictive value for endometrial cancer in this specific setting. In plain language: among people with postmenopausal bleeding and a properly measured thin lining, cancer is very unlikely—but not literally impossible.

The threshold helps clinicians decide whether further endometrial evaluation is warranted; it is not a cancer verdict. A measurement above the local threshold generally leads to additional assessment, often tissue sampling and sometimes hysteroscopy. A lining that is irregular, not fully visible or accompanied by a focal abnormality can also change the plan. Persistent or recurrent bleeding matters even with a thin measurement because uncommon cancers can present with a thin endometrium. See Maple’s Canadian guide to bleeding after menopause.

An incidental measurement without bleeding is a different question

A measurement found incidentally in a postmenopausal person who is not bleeding should not automatically be judged by the postmenopausal-bleeding cutoff. SOGC Guideline No. 451 specifically says those biopsy indications should not be extrapolated to asymptomatic women. The guideline uses a substantially higher measurement, other concerning ultrasound features and individual risk factors to decide who may need further investigation. It also advises against using TVUS as a screening test for endometrial cancer in asymptomatic women.

Perimenopause is different

Before menopause, ovarian hormones and ovulation can still make the lining grow and shed. Thickness can change across a cycle, and cycles may become irregular or anovulatory during perimenopause. A single millimetre measurement therefore cannot be interpreted as though the person were postmenopausal.

Assessment of abnormal perimenopausal bleeding uses the broader clinical picture: age, bleeding pattern and persistence, pregnancy possibility, anemia, medications, risk factors, examination, ultrasound structure and whether tissue sampling is indicated. The postmenopausal 4-mm threshold is not a universal perimenopause rule.

MHT/HRT changes the context too

Bleeding assessment during MHT depends on whether treatment is continuous combined or sequential/cyclic, when it was started or changed, expected withdrawal bleeding, adherence, estrogen and progestogen doses, bleeding heaviness or persistence and individual risk factors. Current British Menopause Society guidance, for example, uses different TVUS thresholds when the lining is uniform and fully visualized: 4 mm or less for continuous-combined HRT and 7 mm or less for sequential HRT. Those numbers belong to that complete clinical pathway; they are not stand-alone rules to apply to every MHT user.

Canadian local pathways and specialist judgment may differ. New bleeding after established amenorrhea, heavy or persistent bleeding, concerning ultrasound features or relevant risk factors may require investigation even when treatment could be contributing. Maple’s Canadian MHT/HRT guide explains the main regimen differences.

“My lining is thick—does that mean cancer?”

No. A thicker measurement can reflect ongoing cycle activity, hormonal stimulation, MHT context, a polyp, hyperplasia, measurement limitations or other structural and clinical circumstances. Cancer is one possibility clinicians are careful not to miss, but thickness alone cannot diagnose it. Conversely, ultrasound cannot certify that tissue is benign because it does not examine cells microscopically.

Ultrasound, biopsy and hysteroscopy: three different views

• Ultrasound shows us what the uterus and lining look like. It can assess uterine anatomy, lining thickness and appearance, fibroids, possible polyps or other focal changes, and ovarian/adnexal structures.
• Biopsy tells us what the sampled tissue looks like under a microscope. Pathologists can assess gland architecture, cellular appearance, hormonal patterns, hyperplasia, atypia/EIN, malignancy and other histological findings.
• Hysteroscopy lets a clinician actually look inside the uterine cavity. It can locate a focal lesion and permit targeted sampling or treatment.

None of these is simply interchangeable with the others.

“My ultrasound was normal. Why might I still need a biopsy?”

A reassuring ultrasound may be enough in some first episodes of postmenopausal bleeding when the lining is thin, clearly seen and bleeding does not recur. It does not mean everyone needs a biopsy. Sampling may still be considered when bleeding persists or returns, the endometrium was not fully visualized, risk factors or other findings change the level of concern, or the overall clinical picture is not explained by the scan.

“My biopsy was benign. Why might I need ultrasound or hysteroscopy?”

A benign biopsy is reassuring pathology from the tissue obtained. But office biopsy is a small, blind sample: it can answer a tissue question while missing the location of a focal structural lesion. When bleeding continues or recurs, ultrasound may look for a polyp, fibroid or other structural explanation, while hysteroscopy can directly inspect the cavity and target an abnormal area. Further investigation does not mean the benign result was meaningless; it means the tests answer different questions.

After an uncomplicated office biopsy

Cramping and light spotting are common. A pad may be useful; follow the clinic’s instructions about tampons, intercourse, bathing, exercise and medications. Some people return to work or normal activity the same day; others need rest.

Driving depends partly on how you feel and whether you received an anxiolytic, opioid, sedating medication or anaesthesia. Do not assume you can drive after sedating medication. Confirm transportation requirements before the appointment.

Contact the clinic or seek medical care for

• heavy bleeding beyond the amount described in your discharge instructions;
• severe or worsening pelvic or abdominal pain;
• fever, chills or feeling significantly unwell;
• foul-smelling or otherwise concerning discharge;
• fainting or another serious symptom; or
• anything your procedure team specifically told you requires review.

What happens while you wait for results?

The sample is accessioned by the laboratory, processed into paraffin blocks, cut into extremely thin sections, placed on slides, stained and examined under a microscope by a pathologist. Additional levels, stains, specialist review or molecular testing may be needed.

Turnaround varies across Canadian pathology services and health authorities, and with urgency, workload, extra testing and the clinician’s communication workflow. Do not rely on a universal number of days. Before leaving, ask: When should I expect the result? How will I receive it? Who will contact me? Who should I call if I have not heard by then?

What the pathologist is actually looking at

Pathology is more sophisticated than “cancer: yes or no.” The pathologist asks whether adequate endometrial tissue is present, how the glands are shaped and spaced, the relationship between glands and supporting stroma, whether cells look hormonally active or atypical, and whether architecture suggests abnormal proliferation or malignancy.

A benign biopsy—but the bleeding returns

A reassuring biopsy is genuinely useful information about the sample obtained. It is not identical to looking at the whole cavity. Polyps and other focal lesions can be missed by blind sampling. Persistent or recurrent postmenopausal bleeding therefore deserves reassessment even after a benign biopsy; that does not mean the original result was useless or that cancer is now assumed.

Questions to ask before the appointment

• Why are you recommending this in my case, and what are you looking for?
• Does it need to happen today?
• What pain-control options do you offer?
• What should I take beforehand, if anything, and do my medications matter?
• What happens if I cannot tolerate the office biopsy?
• Can I drive afterward given the medication plan?
• What bleeding and cramping should I expect, and what symptoms require help?
• When should pathology be available, and how will I receive the result?
• What happens if it is benign but the bleeding returns?

Maple’s appointment-preparation guide, menopause glossary and Canadian care-navigation guide can help you organize the questions and follow-up.

Sources

• ACOG: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding (reaffirmed 2023).
• British Menopause Society: Management of Unscheduled Bleeding on HRT (reviewed 2026).
• ACOG Clinical Consensus: Pain Management for In-Office Uterine and Cervical Procedures (2025).
• Charoenkwan K, et al. Methods of pain control during endometrial biopsy: systematic review and meta-analysis of randomized trials. J Obstet Gynaecol Res. 2020.
• SOGC Guideline No. 451: Asymptomatic Endometrial Thickening in Postmenopausal Women (2024).
• AAGL–ESGE–GCH Joint Society Guideline: Visually Directed Hysteroscopic Biopsy in AUB and PMB (2026).
• ACOG: Management of EIN or Atypical Endometrial Hyperplasia (2023).
• Singh N. Endometrium at menopause: the pathologist’s view. J Midlife Health. 2022.

Educational information only. This page cannot interpret an individual pathology report or decide which procedure is appropriate. Reviewed September 1, 2026.